1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints

from Plenary Session - inactive due to federal service · host Plenary Session

Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.

What this episode covers

NOW PLAYING

0:00 33:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 33 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on September 20, 2018.

What is this episode about?

Can I download this Plenary Session - inactive due to federal service episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!